JP2022538733A5 - - Google Patents

Info

Publication number
JP2022538733A5
JP2022538733A5 JP2021569336A JP2021569336A JP2022538733A5 JP 2022538733 A5 JP2022538733 A5 JP 2022538733A5 JP 2021569336 A JP2021569336 A JP 2021569336A JP 2021569336 A JP2021569336 A JP 2021569336A JP 2022538733 A5 JP2022538733 A5 JP 2022538733A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
sequence
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021569336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538733A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/064154 external-priority patent/WO2020234399A1/en
Publication of JP2022538733A publication Critical patent/JP2022538733A/ja
Publication of JP2022538733A5 publication Critical patent/JP2022538733A5/ja
Pending legal-status Critical Current

Links

JP2021569336A 2019-05-20 2020-05-20 新規抗cd25抗体 Pending JP2022538733A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19305640.5 2019-05-20
EP19305640 2019-05-20
US201962924579P 2019-10-22 2019-10-22
US62/924,579 2019-10-22
US202062965784P 2020-01-24 2020-01-24
US62/965,784 2020-01-24
PCT/EP2020/064154 WO2020234399A1 (en) 2019-05-20 2020-05-20 Novel anti-cd25 antibodies

Publications (2)

Publication Number Publication Date
JP2022538733A JP2022538733A (ja) 2022-09-06
JP2022538733A5 true JP2022538733A5 (enExample) 2023-05-24

Family

ID=70740676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569336A Pending JP2022538733A (ja) 2019-05-20 2020-05-20 新規抗cd25抗体

Country Status (5)

Country Link
US (1) US20220251232A1 (enExample)
EP (1) EP3972997A1 (enExample)
JP (1) JP2022538733A (enExample)
CN (1) CN114630838A (enExample)
WO (1) WO2020234399A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4247497A1 (en) * 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-cd25 antibodies
JP2024504547A (ja) * 2020-11-20 2024-02-01 インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) 抗cd25抗体
US20250101126A1 (en) 2021-08-05 2025-03-27 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
JP2024532790A (ja) * 2021-08-09 2024-09-10 南京▲諾▼艾新生物技▲術▼有限公司 組換え抗ヒトcd25抗体及びその使用
EP4396232A1 (en) 2021-09-03 2024-07-10 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
CN118354789A (zh) 2021-09-03 2024-07-16 Go医疗股份有限公司 抗糖-cMET抗体及其用途
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
TW202444760A (zh) * 2023-03-29 2024-11-16 日商第一三共股份有限公司 抗cd25抗體及抗cd25抗體-藥物複合體
WO2024213046A1 (en) * 2023-04-11 2024-10-17 Suzhou Transcenta Therapeutics Co., Ltd. Anti-cd25 antibody and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
ATE361759T1 (de) 1993-07-15 2007-06-15 Cancer Res Campaign Tech Verbindungen die zur herstellung von protein- tyrosin-kinase-inhibitor-prodrogen verwendet werden können
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP1206260A4 (en) 1999-06-30 2002-10-30 Merck & Co Inc SRC-KINASE INHIBITING COMPOUNDS
EP1194152A4 (en) 1999-06-30 2002-11-06 Merck & Co Inc Links to SRC kinase inhibition
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
AU779908B2 (en) 1999-09-10 2005-02-17 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2387351C (en) 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2450562A1 (en) 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
US6958340B2 (en) 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
WO2007109571A2 (en) 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
PL2602323T3 (pl) 2007-06-01 2018-06-29 Open Monoclonal Technology, Inc. Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
EP3649153B8 (en) * 2017-07-06 2025-07-16 Tusk Therapeutics Ltd Fc optimised anti-cd25 antibodies for tumor specific cell depletion
US10752691B2 (en) * 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents

Similar Documents

Publication Publication Date Title
JP2022538733A5 (enExample)
US12264198B2 (en) Tandem diabody for CD16A-directed NK-cell engagement
US20220340676A1 (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
CN107532188B (zh) Cd20结合分子及其用途
ES2376751T3 (es) Construcciones de unión y métodos para el uso de las mismas
CN112210010B (zh) 抗-人4-1bb抗体及其应用
KR102340832B1 (ko) 항 pd-1 항체 및 그의 용도
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
JP2020528768A5 (enExample)
JP2020525032A5 (enExample)
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
JP2025508118A (ja) 新規免疫調節剤の開発および使用
RU2019121106A (ru) Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
CN121263449A (zh) Cd19/cd38多特异性抗体
JP2022517216A5 (enExample)
US20250051473A1 (en) Anti-cd38 binding molecules and uses thereof
JP2021521201A5 (enExample)
IL277899B2 (en) Methods and preparations for treating yellow fever
JP2023550446A5 (enExample)
EP4448095A1 (en) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
KR20260062933A (ko) 항-γδ TCR 항체 및 이의 용도
AU2023329055A1 (en) Cancer treatment comprising an anti-msln/cd137 antibody and a chemotherapeutic
CN121752599A (zh) 抗γδTCR抗体及其用途
EA052500B1 (ru) Новые антитела против cd24
RU2019138407A (ru) Антитела, направленные на эпитопы, расположенные в области 160-200 аминокислотных оснований белка PRAME человека, и их применение